Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective.
Grit GF, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, Jm Smit H, Brocken P, Fh Eijsink J, Dronkers E, Gal P, Jaarsma E, Jhm van Drie-Pierik R, Mp Eldering-Heldens A, Machteld Wymenga AN, Gm Mol P, Zwaveling J, Hilarius D.
Grit GF, et al. Among authors: gal p.
Lung Cancer. 2024 Oct;196:107950. doi: 10.1016/j.lungcan.2024.107950. Epub 2024 Aug 30.
Lung Cancer. 2024.
PMID: 39236576
Free article.